^
    Back
    Association details:
    Biomarker:PD-L1 expression
    Cancer:Non Small Cell Lung Cancer
    Drug:Jemperli (dostarlimab-gxly) (PD1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Lung Cancer
    Title:

    Safety and Efficacy of Dostarlimab in Patients with Recurrent/Advanced Non-Small Cell Lung Cancer: Results from Cohort E of the Phase I GARNET Trial

    Published date:
    05/23/2022
    Excerpt:
    The median duration of response of 11.6 months (range: 2.8–19.4). Responses were observed in 2/24 (16.7%) patients with PD-L1 TPS <1%, 4/20 (20.0%) patients with PD-L1 TPS 1–49% and 2/5 (40.0%) patients with PD-L1 TPS ≥50%....Dostarlimab demonstrated promising antitumor activity in advanced/recurrent NSCLC that progressed following platinum-based chemotherapy, including across all PD-L1 subgroups, and has an acceptable safety profile.
    DOI:
    https://doi.org/10.1016/j.cllc.2022.05.013
    Trial ID:
    GARNET